Integra Lifesciences Holdings (IART) Price to Sales (2009 - 2026)

Integra Lifesciences Holdings has disclosed Price to Sales across 18 years of filings, most recently posting 3.34 for Q2 2026.

• In Q2 2026, Price to Sales rose 45.01% year-over-year to 3.34; the TTM figure through Jun 2026 stood at 0.85 (up 43.81% YoY), while the FY2025 annual figure was 0.59, down 45.56% from the prior year.
• Price to Sales came in at 3.34 for Q2 2026 at Integra Lifesciences Holdings, up from 1.87 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 14.18 in Q1 2022 to a low of 1.87 in Q1 2026.
• Average Price to Sales over 5 years is 6.74, with a median of 6.49 recorded in 2024.
• The largest YoY upside for Price to Sales was 45.01% in 2026 against a maximum downside of 58.13% in 2026.
• Over 5 years, Price to Sales stood at 11.5 in 2022, then declined by 25.4% to 8.58 in 2023, then tumbled by 53.89% to 3.96 in 2024, then sank by 43.75% to 2.23 in 2025, then surged by 49.87% to 3.34 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 3.34 in Q2 2026, 1.87 in Q1 2026, and 2.23 in Q4 2025.